Reports >
Life Sciences
>
Companion Diagnostics Market Report
Companion Diagnostics Market Report
First published: 15 October 2024 | Last updated: 25 May 2026 | Report Code: companion-diagnostics
Companion Diagnostics Market — USD 6.8 billion in 2023, Growing to USD 17.73B by 2033 at 9.7% CAGR
This report provides an in-depth analysis of the Companion Diagnostics market from 2023 to 2033, showcasing trends, market size, industry dynamics, regional insights, and leading players to inform strategic decision-making.
Key Takeaways
- Global market expands from $6.80 Billion in 2023 to $17.73 Billion by 2033 at a 9.7% CAGR.
- North America is largest regional market, while no single fastest-growing region is stated because regional CAGR differences remain within 0.15 percentage points.
- Europe grows from $2.00 Billion to $5.22 Billion between 2023 and 2033, reflecting strong adoption in clinical settings.
- Top companies include Roche Diagnostics, Agilent Technologies, Thermo Fisher Scientific, Illumina, Inc., and Foundation Medicine.
- Technological advances, regulatory support, and personalized medicine are primary trends supporting market expansion.
Companion Diagnostics Market Report — Executive Summary
North America remains largest market by forecast-period value, while no single fastest-growing region is stated because top regional growth rates are separated by less than 0.15 percentage points. The companion diagnostics field is advancing through increased alignment with targeted therapies and personalized care models. Market growth is underpinned by investments in diagnostic R&D, regulatory pathways that facilitate product introduction, and integration of advanced analytics to improve test performance. The report examines market sizing, regional trajectories, and product and end-user segmentation, and profiles major stakeholders such as Roche Diagnostics, Agilent Technologies, Thermo Fisher Scientific, Illumina, Inc., and Foundation Medicine. Key trends include innovation in molecular and immunodiagnostics, expanding clinical applications in oncology and infectious diseases, and partnerships that accelerate diagnostic development and commercialization.
Key Growth Drivers
- Rising demand for targeted therapies guiding increased use of diagnostic assays and biomarkers.
- Advances in molecular diagnostics and digital pathology enhancing test accuracy and shortening turnaround times.
- Regulatory pathways that support faster approval and clinical integration of companion tests.
- Heightened investment in R&D by diagnostics firms and collaborations between industry and healthcare providers.
- Growing focus on personalized medicine and patient-centric treatment selection driving adoption.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $6.80 Billion |
| CAGR (2023-2033) | 9.7% |
| 2033 Market Size | $17.73 Billion |
| Top Companies | Roche Diagnostics, Agilent Technologies, Thermo Fisher Scientific, Illumina, Inc., Foundation Medicine |
| Published Date | 15 October 2024 |
| Last Modified Date | 25 May 2026 |
Companion Diagnostics Market Overview
Customize Companion Diagnostics Market Report market research report
- ✔ Get in-depth analysis of Companion Diagnostics market size, growth, and forecasts.
- ✔ Understand Companion Diagnostics's regional dynamics and industry-specific trends.
- ✔ Identify potential applications, end-user demand, and growth segments in Companion Diagnostics
What is the Market Size & CAGR of Companion Diagnostics Market Report market in 2023?
Companion Diagnostics Industry Analysis
Companion Diagnostics Market Segmentation and Scope
Tell us your focus area and get a customized research report.
Companion Diagnostics Market Report Market Analysis Report by Region
Europe Companion Diagnostics Market Report:
Europe grows from $2 Billion in 2023 to $5.22 Billion in 2033. Regional expansion is supported by growing integration of companion tests in clinical pathways, regulatory frameworks that enable adoption, and ongoing R&D activity.Asia Pacific Companion Diagnostics Market Report:
Asia Pacific grows from $1.25 Billion in 2023 to $3.27 Billion in 2033. Growth is driven by expanding healthcare infrastructure, rising demand for precision therapies, and increasing local investment in diagnostic technologies.North America Companion Diagnostics Market Report:
North America is largest regional market, rising from $2.55 Billion in 2023 to $6.66 Billion in 2033. The region’s scale reflects strong clinical adoption, a concentration of industry leaders, and significant investment in diagnostic innovation and partnerships.South America Companion Diagnostics Market Report:
Latin America grows from $0.39 Billion in 2023 to $1.01 Billion in 2033. Market progress is linked to broader access to targeted treatments, gradual enhancement of laboratory capabilities, and growing clinical awareness of companion testing.Middle East & Africa Companion Diagnostics Market Report:
Middle East and Africa grows from $0.6 Billion in 2023 to $1.57 Billion in 2033. Development is supported by healthcare modernization efforts, partnerships that transfer diagnostic know-how, and increasing uptake of personalized medicine approaches.Tell us your focus area and get a customized research report.
Research Methodology
Companion Diagnostics Market Analysis By Test Type
The Biomarker Testing segment leads the Companion Diagnostics market, expected to reach USD 14.55 billion by 2033 from USD 5.58 billion in 2023. Genetic Testing is also significant, projected to grow from USD 1.22 billion to USD 3.18 billion over the same period. The dominance of these segments underscores the critical role of biomarker and genetic tests in patient-specific therapeutic regimens.
Companion Diagnostics Market Analysis By Indication
Oncology remains the primary indication for Companion Diagnostics, projected to expand from USD 4.57 billion in 2023 to USD 11.92 billion by 2033. Cardiology and Infectious Diseases are also vital segments, reflecting the increasing diagnostic needs for specialized treatment pathways.
Companion Diagnostics Market Analysis By End User
Hospitals lead the market as the primary end-user, expected to grow from USD 4.57 billion in 2023 to USD 11.92 billion by 2033, retaining a market share of 67.21%. Clinics and Research Institutes also play essential roles but to a lesser extent, indicating the central role hospitals have in delivering personalized patient care.
Companion Diagnostics Market Analysis By Technology
Recent advancements in molecular diagnostics and immunodiagnostics are influencing the Companion Diagnostics landscape. Molecular diagnostics is anticipated to continue its leading position, projected to account for a significant share due to its high accuracy in detecting targeted diseases. Immunodiagnostics, with their application in oncology and infectious diseases, are also expanding rapidly.
Companion Diagnostics Market Analysis By Region Needless
Global Companion Diagnostics Market, By Region (Omitted as per instructions) Market Analysis (2023 - 2033)
This segment would typically provide insights about regional market characteristics and variations, but it has been omitted as per the request.
Companion Diagnostics Market Trends and Future Forecast
Tell us your focus area and get a customized research report.
Global Market Leaders and Top Companies in Companion Diagnostics Industry
Roche Diagnostics:
A pioneer in diagnostics and a leader in Companion Diagnostics, Roche provides innovative solutions integrating diagnostics to enhance personalized healthcare, with a focus on oncology biomarkers.Agilent Technologies:
Known for their advanced diagnostic technologies, Agilent focuses on enhancing precision medicine through cutting-edge biomarker discovery and providing a comprehensive suite of diagnostic solutions.Thermo Fisher Scientific:
Thermo Fisher offers a range of Companion Diagnostics solutions, striving to facilitate personalized treatment decisions through robust testing methodologies and a broad product portfolio.Illumina, Inc.:
Illumina is highly regarded for its genomic sequencing technologies, playing a crucial role in enabling genomic profiling for personalized medicines in the market.Foundation Medicine:
Specializing in genomic profiling of cancer, Foundation Medicine offers comprehensive tests that aid in identifying targeted therapies for patients, reinforcing the role of CDx in oncology.We're grateful to work with incredible clients.
FAQs
What is the current market size of companion diagnostics?
The market size for companion diagnostics was $6.80 Billion in 2023, reflecting the value of diagnostic tests that guide targeted therapies and patient selection for specific treatments.
How big is the market expected to be in 2033?
By 2033 the market is projected to reach $17.73 Billion, driven by technology adoption, expanded clinical use, and increased investment in diagnostic development across regions.
What is CAGR for the forecast period?
The forecast period CAGR is 9.7% for 2023 to 2033, representing compound annual growth based on the provided market values for 2023 and 2033.
Is there a single fastest Growing region in the Companion Diagnostics Market Report market?
No single fastest-growing region is stated for the Companion Diagnostics Market Report market because the top regional implied CAGR values are within 0.15 percentage points of each other, making the ranking too close to call reliably.
Which companies lead the companion diagnostics sector?
Leading organizations named include Roche Diagnostics, Agilent Technologies, Thermo Fisher Scientific, Illumina, Inc., and Foundation Medicine, each active in diagnostics development and commercialization.
What are primary trends affecting this market?
Key trends include technological innovation in diagnostics, regulatory evolution enabling product approvals, and a growing emphasis on personalized medicine shaping test development and deployment.
How big is the European market in 2023 and 2033?
Europe’s market size moves from $2.00 Billion in 2023 to $5.22 Billion in 2033, reflecting rising clinical uptake and investment in diagnostic capabilities across the region.
What drives adoption in Asia Pacific?
Asia Pacific increases from $1.25 Billion in 2023 to $3.27 Billion in 2033, driven by expanding healthcare infrastructure, rising demand for precision medicine, and local investment in diagnostics.
Who are typical end users of companion diagnostics?
End users include hospitals, clinics, and research institutes, which utilize companion tests to match patients with appropriate therapeutic regimens and inform clinical decision-making.
Why is diagnostic innovation important for oncology?
Diagnostics inform targeted oncology therapies by identifying biomarkers and genetic profiles, improving patient selection and treatment outcomes while supporting precision oncology development.